DOI: 10.12890/2016_000396

Spontaneous Cirrhosis Regression in an IFN-beta-induced AIH-like Syndrome Following Drug Withdrawal: Art of Facts or Artifacts?

Authors

  • Maria Kalafateli Department of Gastroenterology, University Hospital of Patras
  • Christos Triantos Department of Gastroenterology, University Hospital of Patras
  • Athanasios Tsamandas Department of Pathology, University Hospital of Patras
  • George N Dalekos Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Larissa http://www.med.uth.gr/internalmedicine/index.php/el/

georgedalekos@gmail.com

Keywords

Autoimmune hepatitis, cirrhosis, drug-induced liver injury, interferon-beta, multiple sclerosis.

Abstract

Autoimmune hepatitis (AIH) is a disease of unknown aetiology with drug-induced AIH being the most complex and not fully understood type. We present the case of a 57-year-old female patient with acute icteric hepatitis after interferon-beta-1b (IFN?-1b) administration for multiple sclerosis (MS). Based on liver autoimmune serology, histology and appropriate exclusion of other liver diseases, a diagnosis of AIH-related cirrhosis was established. Following discontinuation of IFN?-1b, a complete resolution of biochemical activity indices was observed and the patient remained untreated on her own decision. However, 3 years later, after a course of intravenous methylprednisolone for MS, a new acute transaminase flare was recorded which subsided again spontaneously after 3 weeks. Liver biopsy and elastography showed significant fibrosis regression (F2 fibrosis). To our knowledge, this is the first report showing spontaneous cirrhosis regression in an IFN?-1b-induced AIH-like syndrome following drug withdrawal, suggesting that cirrhosis might be reversible if the offending fibrogenic stimulus is withdrawn.

View the entire article

Downloads

Additional Files

References

  1. Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, et al. Review article: autoimmune hepatitis - current management and challenges. Aliment Pharmacol Ther 2013;38:887–913.
  2. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015;63:971–1004.
  3. Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, et al. Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol 2012;137:5–9.
  4. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol 2011;55:636–646.

Published

2016-06-07

Issue

Vol. 3 No. 4 (2016)

How to Cite

1.
Kalafateli M, Triantos C, Tsamandas A, Dalekos GN. Spontaneous Cirrhosis Regression in an IFN-beta-induced AIH-like Syndrome Following Drug Withdrawal: Art of Facts or Artifacts? EJCRIM [Internet]. 2016 Jun. 7 [cited 2026 Nov. 3];3(4). Available from: https://ejcrim.com/index.php/ejcrim/article/view/396